NCT01936883Active, not recruiting
Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy
IMPROVING QUALITY OF LIFE AFTER OPTIMAL RADIOTHERAPY FOR INTERMEDIATE AND HIGH RISK PROSTATE CANCER: A Randomized Comparison of HDR Versus LDR BRACHYTHERAPY BOOST
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
Optimal non surgical treatment of prostate cancer requires dose escalation which is frequently provided by adding a brachytherapy "boost" to a short course of external beam radiotherapy. The hypothesis in this randomized study is that a High Dose Rate (HDR) brachytherapy boost leads to equivalent or better Prostate Specific Antigen (PSA) recurrence-free survival when compared to a Low Dose Rate (LDR) brachytherapy boost and that it is associated with a more favorable toxicity profile and improved quality of life.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 195 (actual)
- First submitted
- 3 Sept 2013
- Start date
- 1 Jan 2014
- Primary completion date
- 31 Dec 2019
- Lead sponsor
- British Columbia Cancer Agency
- Diseases
- Prostate cancer
- NCT number
- NCT01936883
What you commit to
- Study type: Interventional
- Participants enrolled: 195
- From 1 Jan 2014 to the primary completion date, 31 Dec 2019
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous prostatectomy, cryotherapy or High Intensity Focussed Ultrasound for prostate cancer
- Previous pelvic irradiation or prostate brachytherapy
Other illness
- Prior invasive malignancy (except non melanoma skin cancer) unless disease-free for at least 3 years prior to registration
Who the study is looking for
- Upper tier intermediate risk with at least 2 of the following factors
- Tumor-Nodes-Metastases Tumor stage T2B or greater
- Gleason Score 7
- PSA \> 10
- \> 50% of the biopsies positive
- OR High risk prostate cancer with one of the following factors
- T3a
- Gleason Score8-10
- PSA \>20
- Positive prostate biopsy within 12 months (reviewed centrally)
- International Prostate Symptom Score \< 16
- Prostate volume \< 60 cc
- Negative staging CT and Bone scan within 3 months prior to registration
- History and physical examination within 90 days prior to registration
- European Cooperative Oncology Group performance status 0-1 prior to registration
- Age \>45
- Patient suitable for procedure under anesthesia
Age in the registry: 45 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| British Columbia Cancer Agency Center for the Southern Interior Coordinator of this site? Confirm its status | Kelowna | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.